Pharma News

Merck has announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a supplemental Biologics License Application (sBLA) for Winrevair (sotatercept-csrk).

In a major scientific breakthrough, researchers from McMaster University, Cleveland Clinic, and the Case Comprehensive Cancer Center have uncovered how a protein commonly linked to Alzheimer’s disease also plays a critical role in the spread of lung cancer to the brain. The discovery could pave the way for repurposing existing Alzheimer’s drugs to halt or slow brain metastases in cancer patients.

Researchers at the University of Illinois Urbana-Champaign have developed an innovative magnetic resonance imaging (MRI) method capable of noninvasively mapping metabolic activity in the brain, offering new insights into neurological diseases.

Pfizer unveiled very encouraging topline results from its Phase 3 BASIS clinical trial (NCT03938792). The study examined once‑weekly, under‑skin injections of HYMPAVZI (marstacimab) in adolescents and adults (12 years+) living with hemophilia A or B complicated by inhibitors an antibody that can neutralize traditional factor replacement therapy.

Vertex Pharmaceuticals has announced that the European Commission has approved its newest cystic fibrosis treatment, ALYFTREK a once-daily, triple-combination therapy made up of deutivacaftor, tezacaftor, and vanzacaftor.

In a landmark study published recently in Chinese Neurosurgical Journal, Chinese researchers have identified the protein FAM111B as a crucial molecular accelerator in glioma, the most common and deadly form of primary brain cancer in adults.

Researchers at the University of Texas at Arlington (UTA) have identified a novel molecular mechanism by which chronic inflammation impairs cholesterol metabolism, potentially paving the way for new therapeutic strategies targeting inflammatory diseases and cardiovascular disorders.

In a significant development for global health, Hyderabad-based Biological E. Limited has joined hands with Chinese biopharmaceutical firm Jiangsu Recbio Technology Company Limited to produce and distribute the 9-valent Human Papillomavirus (HPV9) vaccine, REC603.

Alembic Pharmaceuticals Limited has announced that it has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection in two strengths: 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials.